# A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

> **NCT06255223** · PHASE2 · RECRUITING · sponsor: **Jinling Hospital, China** · enrollment: 35 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Radiotherapy
- Immune Checkpoint Inhibitor

## Interventions

- **RADIATION:** High-dose Radiotherapy (HDRT)
- **RADIATION:** Low-dose Radiotherapy (LDRT)
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06255223
- **Lead sponsor:** Jinling Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-15
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06255223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06255223, "A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06255223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*